CryoPort, Inc. CYRX
17.41
0.01
0.06%
as of 25 Sep
- Market cap
- $881.3M
- P/E
- 0.0×
Follow CYRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 6.13 | 7.27 | 8.10 |
+8 more quarters Free account |
P/S ratio |
4.25 | 2.26 | 2.73 | 2.76 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
700.23 | 110.62 | 523.06 | 217.18 | |
P/B ratio |
1.78 | 0.92 | 1.04 | 1.00 | |
Price to Tangible BV |
2.77 | 1.43 | 1.60 | 1.54 | |
EV/Sales |
3.13 | 1.08 | 1.46 | 1.48 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
73.10 | (391.21) | (29.90) | (17.04) | |
EV/FCF |
(27.30) | (7.51) | (9.14) | (7.26) | |
Quick Ratio |
1.96 | 1.97 | 2.03 | 14.84 | |
Current Ratio |
2.08 | 2.09 | 2.17 | 15.77 | |
Net Debt/EBITDA |
66.35 | 74.20 | 66.31 | 72.72 | |
Debt/Assets |
24.80% | 24.52% | 24.46% | 24.14% | |
Debt/Equity |
0.38 | 0.38 | 0.37 | 0.36 | |
Asset Turnover |
0.24 | 0.25 | 0.24 | 0.23 | |
Operating CF/Net income |
(0.11) | (0.30) | (0.07) | (0.24) | |
Capex/Depreciation |
(1.42) | (1.54) | (0.74) | (0.64) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.91% | 8.17% | 9.83% | 10.23% | |
Selling, General and Administrative Expense of Revenue |
57.20% | 57.78% | 60.01% | 60.44% | |
Intangible Assets out of Total Assets |
0.21 | 0.21 | 0.21 | 0.21 | |
Share Based Compensation of Revenue |
4.90% | 5.01% | 5.35% | 5.71% | |
Graham Net Nets |
0.25 | 0.49 | 0.44 | 0.47 | |
Graham Number |
0.00 | 16.56 | 16.52 | 15.76 | |
Earnings Yield |
(5.73%) | 16.30% | 13.75% | 12.34% | |
Free Cash Flow Yield |
(2.70%) | (6.34%) | (5.84%) | (7.40%) | |
Revenue per Share |
0.97 | 0.96 | 0.91 | 0.88 | |
Operating CF per Share |
0.02 | 0.07 | 0.02 | 0.04 | |
Capex per Share |
(0.19) | (0.21) | (0.10) | (0.09) | |
Free Cash Flow per Share |
(0.17) | (0.13) | (0.08) | (0.04) | |
Cash per Share |
7.86 | 8.09 | 8.21 | 8.41 | |
Shareholders Equity per Share |
9.73 | 9.92 | 10.04 | 10.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.73 | 9.92 | 10.04 | 10.24 | |
Free Cash Flow |
(8.68) | (6.55) | (4.02) | (2.09) | |
Working Capital |
239.17 | 245.67 | 257.16 | 454.09 | |
Capital Expenditures |
(9.81) | (10.28) | (4.94) | (4.28) | |
Net Current Asset Value |
194.70 | 201.92 | 213.82 | 223.79 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.20 | 0.22 | 0.11 | 0.10 | |
Net Profit Margin |
(20.94%) | (26.24%) | (30.02%) | (20.22%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
34.93 | 33.69 | 29.33 | 39.19 | |
Average Payables |
15.50 | 14.69 | 15.59 | 19.54 | |
Average Inventory |
22.27 | 22.55 | 22.33 | 23.44 | |
Average Assets |
765.07 | 731.73 | 734.24 | 738.05 | |
Average Common Equity |
460.77 | 406.63 | 413.99 | 429.65 |
Columns are period end dates